WEE1 and cancer: Several studies have shown that mTOR activation status significantly affects the sensitivity to WEE1 inhibition in cancer cells (17–19), whereas Pfister et al. reported that H3K36me3-deficient cancers are acutely sensitive to WEE1 inhibition (20).